Swedish institutional and private investors.
Trimb Healthcare holds a portfolio of over-the-counter (OTC) healthcare products treating and preventing conditions such as high cholesterol and blood glucose, red eyes, rhinitis, snoring and nosebleeds. Trimb’s most important product, Betavivo, is an oat-based product which is scientifically proven to reduce cholesterol and blood sugar levels without adverse effects. Betavivo is approved in the EU by EFSA.
Convertible issue to existing shareholders and a number of new Swedish institutional and private investors of SEK 55 million to fund further M&A opportunities of OTC products and companies.